Merck & Company Inc (MRK)vsSpero Therapeutics Inc (SPRO)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SPRO
Spero Therapeutics Inc
$2.51
-0.79%
HEALTHCARE · Cap: $154.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 97219% more annual revenue ($65.01B vs $66.80M). MRK leads profitability with a 28.1% profit margin vs 12.8%. MRK trades at a lower P/E of 15.2x. SPRO earns a higher WallStSmart Score of 63/100 (C+).
MRK
Buy59
out of 100
Grade: C
SPRO
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+51.9%
Fair Value
$4.95
Current Price
$2.51
$2.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Strong operational efficiency at 76.0%
Revenue surging 174.5% year-over-year
Earnings expanding 75.3% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SPRO
The strongest argument for SPRO centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 174.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SPRO
The primary concerns for SPRO are Market Cap, Free Cash Flow.
Key Dynamics to Monitor
MRK profiles as a value stock while SPRO is a growth play — different risk/reward profiles.
SPRO carries more volatility with a beta of 1.45 — expect wider price swings.
SPRO is growing revenue faster at 174.5% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
SPRO scores higher overall (63/100 vs 59/100) and 174.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Spero Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?